专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明专利

IL234904D0 Microrna compounds and methods for modulating mir-21 activity 未知
公开(公告)号：IL234904D0
公开(公告)日：2014-12-31
申请号：IL23490414
申请日：2014-07-29
申请人： REGULUS THERAPEUTICS INC
IPC分类号： C12N20060101
摘要： Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

92. 发明专利

SG11201406931XA MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY 未知
公开(公告)号：SG11201406931XA
公开(公告)日：2014-11-27
申请号：SG11201406931X
申请日：2013-04-24
申请人： REGULUS THERAPEUTICS INC
发明人： BHAT BALKRISHEN , MARCUSSON ERIC
IPC分类号： C12N15/113 , A61K31/712 , A61P13/12 , A61P35/00 , A61P43/00
摘要： Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

93. 发明专利

MA35151B1 Composés microarn et procédés pour la modulation de l'activité de mir-21 未知
公开(公告)号：MA35151B1
公开(公告)日：2014-06-02
申请号：MA36437
申请日：2013-11-15
申请人： REGULUS THERAPEUTICS INC
发明人： BHAT BALKRISHEN
IPC分类号： C12N15/113
摘要： La présente invention concerne des compositions et des procédés pour l'inhibition de l'activité de mir-21. Les compositions ont certains motifs de modification de nucléoside qui fournissent des inhibiteurs puissants de l'activité de mir-21. Les compositions peuvent être utilisées pour inhiber mir-21 ainsi que pour traiter des maladies associées à une expression anormale de mir-21, telles qu'une fibrose et un cancer.

94. 发明专利

IL229032D0 Microrna compounds and methods for modulating mir-21 activity 未知
公开(公告)号：IL229032D0
公开(公告)日：2013-12-31
申请号：IL22903213
申请日：2013-10-23
申请人： REGULUS THERAPEUTICS INC
IPC分类号： C12N20060101
摘要： Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

95. 发明专利

AU2012249851A1 Microrna compounds and methods for modulating miR-21 activity 未知
公开(公告)号：AU2012249851A1
公开(公告)日：2013-10-31
申请号：AU2012249851
申请日：2012-04-25
申请人： REGULUS THERAPEUTICS INC
发明人： BHAT BALKRISHEN
IPC分类号： C12N15/113 , A61P35/00
摘要： Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

96. 发明专利

AU2013200489A1 Methods for use in modulating miR-122a 未知
公开(公告)号：AU2013200489A1
公开(公告)日：2013-02-21
申请号：AU2013200489
申请日：2013-01-31
申请人： REGULUS THERAPEUTICS INC
发明人： BHANOT SANJAY , ESAU CHRISTINE
IPC分类号： A61K31/711 , C12N15/113
摘要： METHODS FOR USE IN MODULATING MIR-122A Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.

97. 发明专利

AU2017370560C1 Modified oligonucleotides for treatment of polycystic kidney disease 未知
公开(公告)号：AU2017370560C1
公开(公告)日：2022-08-11
申请号：AU2017370560
申请日：2017-12-04
申请人： REGULUS THERAPEUTICS INC
发明人： ALLERSON CHARLES R
IPC分类号： C07H21/00 , A61K31/712 , A61K31/7125 , A61P13/12 , C12N15/113
摘要： Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

98. 发明专利

AR119688A2 MÉTODOS PARA EL TRATAMIENTO DEL SÍNDROME DE ALPORT 未知
公开(公告)号：AR119688A2
公开(公告)日：2022-01-05
申请号：ARP200100284
申请日：2020-02-03
申请人： REGULUS THERAPEUTICS INC
发明人： DUFFIELD JEREMY , MACKENNA DEIDRE , BHAT BALKRISHEN
IPC分类号： A61K31/7125 , A61P13/12 , C12N15/113
摘要： Se proporcionan en la presente métodos para el tratamiento del Síndrome de Alport, usando oligonucleótidos modificados dirigidos a miR-21. En ciertas realizaciones, un oligonucleótido modificado dirigido a miR-21 mejora la función renal y/o reduce la fibrosis en sujetos que tienen Síndrome de Alport. En ciertas realizaciones, la administración de un oligonucleótido modificado dirigido a miR-21 retrasa el inicio de la enfermedad renal de etapa terminal en un sujeto que tiene Síndrome de Alport. En ciertas realizaciones, un oligonucleótido modificado dirigido a miR-21 retrasa la necesidad de diálisis o trasplante de riñón en un sujeto que tiene Síndrome de Alport.

99. 发明专利

AU2019381681A1 Microrna compounds and methods for modulating miR-10b activity 未知
公开(公告)号：AU2019381681A1
公开(公告)日：2021-05-27
申请号：AU2019381681
申请日：2019-11-12
申请人： REGULUS THERAPEUTICS INC
发明人： ALLERSON CHARLES R
IPC分类号： A61P35/00 , A61K31/712 , C07H21/02
摘要： Described herein are compositions and methods for the inhibition of miR-10b activity. The compositions may be administered to subjects with cancer, such as glioma.

100. 发明专利

ES2621863T9 Compuestos de microARN y métodos para modular la actividad de miR-21 未知
公开(公告)号：ES2621863T9
公开(公告)日：2020-02-13
申请号：ES12718549
申请日：2012-04-25
申请人： REGULUS THERAPEUTICS INC
发明人： BHAT BALKRISHEN
IPC分类号： C12N15/113 , A61P35/00 , A61P43/00

你已经成功收藏专利！

检索式保存成功!

IPRDB